Kalaris Therapeutics KLRS
NASDAQ KLRS
$1.87 -0.12 (-6.03%)
At close: Oct 23, 2026 · 4:00 PM EDT

Kalaris Therapeutics (KLRS) Cash & Current Investments (2019 - 2026)

Updated

Kalaris Therapeutics (KLRS) reported Cash & Current Investments of $93.5 million for Q2 2026, up 5.7% from $88.43 million a year earlier but down 10.9% from the prior quarter.

Analysis

Kalaris Therapeutics (KLRS) Cash & Current Investments (2019 - 2026) Analysis & Trends

At the end of FY2025, Kalaris Therapeutics posted Cash & Current Investments of $118 million, down 0.3% from FY2024.

  • Cash & Current Investments has declined for five consecutive years, with a five-year compound annual growth rate of -19.8% (FY2020 to FY2025).
  • By year, Cash & Current Investments came in at $118.3 million in FY2024 (-35.7%), $183.9 million in FY2023 (-21.3%), $233.8 million in FY2022 (-5.8%) and $248.12 million in FY2021 (-30.4%).
  • Five-year quarterly Cash & Current Investments spans a low of $77,000 in Q3 2025 and a high of $275.84 million in Q3 2021.
  • Year over year, Cash & Current Investments gained in two of the last eight quarters, with an average decline of 28.6%.
  • The high point for year-over-year Cash & Current Investments in five years was Q2 2023 (growth of 42.7%); the low point was Q3 2025 (a decline of 99.9%).
  • Per Business Quant data, the three quarters before Q2 2026 came in at $104.9 million (Q1 2026), $118 million (Q4 2025) and $77,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 17.23 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 6.57 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 7.14 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 7.69 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 4.90 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 3.18 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 11.70 Bn
10 Kalaris Therapeutics 44.52 Mn -48.98 Mn - 93.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 93.50 Mn
Mar 31, 2026 104.90 Mn
Dec 31, 2025 118.00 Mn
Sep 30, 2025 77,000.00
Jun 30, 2025 88.43 Mn
Mar 31, 2025 100.97 Mn
Dec 31, 2024 118.30 Mn
Sep 30, 2024 121.90 Mn
Jun 30, 2024 129.60 Mn
Mar 31, 2024 140.50 Mn
Dec 31, 2023 183.90 Mn
Sep 30, 2023 213.30 Mn
Jun 30, 2023 246.50 Mn
Mar 31, 2023 202.60 Mn
Dec 31, 2022 233.80 Mn
Sep 30, 2022 264.10 Mn
Jun 30, 2022 172.70 Mn
Mar 31, 2022 201.40 Mn
Dec 31, 2021 248.12 Mn
Sep 30, 2021 275.84 Mn
API Access

Kalaris Therapeutics Cash & Current Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-current-investments&ticker=KLRS&period=max&api_key=YOUR_API_KEY